Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
A phase 2 trial of Cinrebafusp alfa, Ramucirumab and Tucatinib in gastric & gastro-oesophageal junction cancer, run by Pieris Pharmaceuticals, Inc., active and no longer recruiting.
Overview
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma is a phase 2 interventional study registered as NCT05190445 by Pieris Pharmaceuticals, Inc., with 80 participants enrolled, started 2021-11-01 and due to reach its primary completion in 2023-02-01. Interventions recorded: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel and Cinrebafusp alfa (PRS-343) in combination with tucatinib.
Similar pages
not linked directly; found by shared links- TrialA Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Shares Ramucirumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialSHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Shares Ramucirumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Shares Ramucirumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Shares Tucatinib, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialTucatinib+Trastuzumab+Eribulin in HER2+ MBC
Shares Tucatinib and the tag pipeline.
- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Tucatinib and the tag pipeline.
- TrialStudy to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialTherapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.